Business · 14/04/2006Updated: 10/17/2026 · 1 min read
FDA Releases Guidance for Exocrine Pancreatic Insufficiency Drug Products
Summary
The Food and Drug Administration (FDA) has made available a guidance document to help manufacturers of exocrine pancreatic insufficiency drug products prepare and submit new drug applications (NDAs) to the FDA.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →